Loading...
XSHE
300233
Market cap726mUSD
Jul 10, Last price  
13.25CNY
1D
1.92%
1Q
-14.07%
Jan 2017
-45.63%
IPO
30.99%
Name

Shandong Jincheng Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300233 chart
P/E
113.75
P/S
1.85
EPS
0.12
Div Yield, %
3.08%
Shrs. gr., 5y
-0.33%
Rev. gr., 5y
-2.84%
Revenues
2.72b
-19.44%
569,929,000584,609,000759,385,000788,421,000799,332,000908,713,1181,050,829,9721,178,560,2991,420,385,0182,788,037,1003,007,968,0482,794,819,3312,961,935,8333,138,454,2803,138,454,2793,505,716,9623,505,716,9613,538,312,4593,373,387,3992,717,540,112
Net income
44m
-77.55%
53,666,00081,348,000104,624,00055,991,00041,611,00064,596,728108,700,720170,977,254159,390,212286,304,090263,863,412203,285,189-488,844,746107,984,095107,984,098273,365,308273,365,315174,709,363196,780,75244,186,259
CFO
321m
+8.18%
30,230,000105,625,000108,674,00062,691,00086,606,00093,922,000219,455,000207,918,000241,482,000151,829,000352,197,000577,983,000546,126,000437,185,000255,627,000664,075,000296,586,000320,840,041
Dividend
Sep 17, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Jincheng Pharmaceutical Group Co., Ltd., together with its affiliated companies, focuses on the global research, development, manufacturing, and distribution of Cephalosporin intermediates. The Group's extensive product line includes active pharmaceutical ingredients (APIs), biopharmaceutical products, various medical intermediates, specialty fine chemicals, and final dosage form medications. Additionally, it diversifies its operations by offering animal nutrition and healthcare products, as well as providing contract manufacturing (CMO) and contract development and manufacturing (CDMO) services. Established in 2004, the company is headquartered in Zibo, China.
IPO date
Jun 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT